BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 10593998)

  • 21. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience.
    Wagner Costalas J; Itzen M; Malick J; Babb JS; Bove B; Godwin AK; Daly MB
    Am J Med Genet C Semin Med Genet; 2003 May; 119C(1):11-8. PubMed ID: 12704633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.
    Yazici H; Bitisik O; Akisik E; Cabioglu N; Saip P; Muslumanoglu M; Glendon G; Bengisu E; Ozbilen S; Dincer M; Turkmen S; Andrulis IL; Dalay N; Ozcelik H
    Br J Cancer; 2000 Sep; 83(6):737-42. PubMed ID: 10952777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
    Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
    Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.
    Sarantaus L; Vahteristo P; Bloom E; Tamminen A; Unkila-Kallio L; Butzow R; Nevanlinna H
    Eur J Hum Genet; 2001 Jun; 9(6):424-30. PubMed ID: 11436123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
    Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland.
    van Der Looij M; Wysocka B; Brozek I; Jassem J; Limon J; Olah E
    Hum Mutat; 2000 May; 15(5):480-1. PubMed ID: 10790213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers.
    Wang WW; Spurdle AB; Kolachana P; Bove B; Modan B; Ebbers SM; Suthers G; Tucker MA; Kaufman DJ; Doody MM; Tarone RE; Daly M; Levavi H; Pierce H; Chetrit A; Yechezkel GH; Chenevix-Trench G; Offit K; Godwin AK; Struewing JP
    Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):955-60. PubMed ID: 11535547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history.
    Rebbeck TR; Wang Y; Kantoff PW; Krithivas K; Neuhausen SL; Godwin AK; Daly MB; Narod SA; Brunet JS; Vesprini D; Garber JE; Lynch HT; Weber BL; Brown M
    Cancer Res; 2001 Jul; 61(14):5420-4. PubMed ID: 11454686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distress in couples approached for genetic counseling and BRCA1/2 testing during adjuvant radiotherapy.
    Schlich-Bakker KJ; ten Kroode HF; Wárlám Rodenhuis CC; Ausems MG; van den Bout J
    Psychooncology; 2009 Sep; 18(9):965-73. PubMed ID: 19140177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Posttraumatic stress associated with cancer history and BRCA1/2 genetic testing.
    Hamann HA; Somers TJ; Smith AW; Inslicht SS; Baum A
    Psychosom Med; 2005; 67(5):766-72. PubMed ID: 16204436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer.
    Hallowell N; Foster C; Eeles R; Ardern-Jones A; Watson M
    Soc Sci Med; 2004 Aug; 59(3):553-65. PubMed ID: 15144764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interest in genetic testing among first-degree relatives of breast cancer patients.
    Lerman C; Seay J; Balshem A; Audrain J
    Am J Med Genet; 1995 Jul; 57(3):385-92. PubMed ID: 7677139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
    Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
    Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Seynaeve C; van Geel AN; Tilanus MM; Bartels CC; Verhoog LC; Brekelmans CT; Burger CW; Niermeijer MF
    Breast Cancer Res Treat; 2002 May; 73(2):97-112. PubMed ID: 12088120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Genetic predisposition to breast cancer: a review in April 1998].
    Stoppa-Lyonnet D
    Contracept Fertil Sex; 1999; 27(7-8):517-20. PubMed ID: 10495568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
    Lerman C; Narod S; Schulman K; Hughes C; Gomez-Caminero A; Bonney G; Gold K; Trock B; Main D; Lynch J; Fulmore C; Snyder C; Lemon SJ; Conway T; Tonin P; Lenoir G; Lynch H
    JAMA; 1996 Jun; 275(24):1885-92. PubMed ID: 8648868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer EJ; Verhoog LC; Brekelmans CT; Seynaeve C; Tilanus-Linthorst MM; Wagner A; Dukel L; Devilee P; van den Ouweland AM; van Geel AN; Klijn JG
    Lancet; 2000 Jun; 355(9220):2015-20. PubMed ID: 10885351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Initial Dutch results with a presymptomatic DNA tests in familial breast/ovarian carcinoma. Rotterdamse Werkgroep voor Erfelijke Tumoren].
    Klijn JG; Devilee P; van Geel AN; Tilanus-Linthorst MM; Dudok-de Wit C; Meijers-Heijboer EJ
    Ned Tijdschr Geneeskd; 1995 Mar; 139(9):439-45. PubMed ID: 7891765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.